Dear Colleagues,

Sarcoidosis is a matter of great interest for clinicians since it can involve almost all organs and tissues, although its clinical burden is related most often to lungs and lymph nodes. Non-caseating and non-necrotizing granulomas are the histopathological hallmarks of the disease. Biopsy of accessible sites represents a valid diagnostic approach. Sometimes the diagnosis is more challenging for sites that are difficult to reach on biopsy but diagnosis can be reasonably achieved by a combination of suggestive clinical and radiological data. The issue becomes complex when extrapulmonary sites are affected without lung involvement (e.g., splenic disease). Sarcoidosis in such cases can mimic other disorders such as malignant tumors and lymphomas.

Current management guidelines are based on the exclusion of other similar disorders, the demonstration of non-caseating granulomas, and the assessment of disease severity and risk stratification.

Spontaneous remission is common in sarcoid lung disease. However, the clinical picture is heterogeneous and some patients require symptomatic relief or a reduction of disease progression with corticosteroids or immunosuppressive agents. For these patients, an adequate follow-up is mandatory, since disease relapse can be associated with clinical deterioration and worse prognosis. In up to 25-30% of patients, sarcoidosis becomes chronic, leaving some patients with permanent disease. Black Americans more often experience severe disease, multi-organ involvement, and the highest risk of hospitalization and mortality which often results from cardiac involvement.

This Special Issue would like to report the most recent evidence about etiology, diagnostic and therapeutic advances on sarcoidosis. Authors are encouraged to submit their experimental studies and reviews about the latest research on this topic. Deadline for submission is planned for 1 December 2023.

Claudio Tana
Guest Editor

Manuscripts should be submitted via our online editorial system at https://www.biolifesas.org/journalx_brha/authorLogOn.action by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. Submitted manuscripts should be well formatted in good English.